Jubilant Pharmova Limited (NSE:JUBLPHARMA)
India flag India · Delayed Price · Currency is INR
945.95
-27.65 (-2.84%)
Jun 8, 2026, 3:30 PM IST

Revenue by Segment

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
Radio Pharma
36.90B33.88B30.01B25.52B21.23B
Radio Pharma Growth
8.92%12.88%17.59%20.24%-
Allergy Immunotherapy
7.96B7.14B6.98B6.03B4.89B
Allergy Immunotherapy Growth
11.41%2.36%15.76%23.15%-
Contract Development and Manufacturing Organization - Sterile Injectables
18.13B13.53B12.04B12.71B14.35B
Contract Development and Manufacturing Organization - Sterile Injectables Growth
34.00%12.31%-5.24%-11.43%-
Contract Research, Development and Manufacturing Organization
12.65B11.73B11.40B12.93B11.48B
Contract Research, Development and Manufacturing Organization Growth
7.85%2.88%-11.82%12.58%-
Generics
7.74B6.85B7.75B7.65B11.62B
Generics Growth
12.87%-11.53%1.23%-34.13%-
Inter-Segment Revenue
-1.16B-1.16B-1.53B-2.28B-2.49B
Unallocable Corporate
585.00M372.00M383.00M218.00M202.49M
Unallocable Corporate Growth
57.26%-2.87%75.69%7.66%-
Proprietary Novel Drugs
---38.00M18.41M
Proprietary Novel Drugs Growth
---106.41%-49.77%
Total
82.80B72.35B67.03B62.82B61.30B
Total Growth
14.45%7.93%6.71%2.47%0.52%

Revenue by Geography

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
India
2.13B1.92B1.91B3.39B
India Growth
10.78%0.73%-43.85%-82.81%
Americas and Europe
65.94B60.12B55.94B53.19B
Americas and Europe Growth
9.67%7.48%5.15%-13.02%
Rest of The World (ROW)
4.28B4.99B4.98B4.71B
Rest of The World (ROW) Growth
-14.17%0.24%5.57%-20.08%
Total
72.35B67.03B62.82B61.30B
Total Growth
7.93%6.71%2.47%0.52%
Source: S&P Global Market Intelligence.